- Argenx deepens immuno expertise with $2.2B Forte Biosciences buyThe star of the takeover is Forte Biosciences' investigational antibody therapy, FB102, which has shown early potential in vitiligo and celiac disease.BioSpace · 1d ago↗ source
- A trend that isn’t fading, ultra-processed baby foodsAn FDA advisory panel serves some peptide wins, a measles record, and more health news from Morning RoundsSTAT · 1d ago↗ source
- STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain diseaseOak Hill Bio, a new company backed by RA Capital and other investors, will take on Ultragenyx and Ionis in developing an Angelman syndrome medicine.STAT · 1d ago↗ source